Drug Profile
Cancer vaccine - MediGene
Latest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator MediGene AG
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Malignant melanoma; Ovarian cancer
Most Recent Events
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 04 Aug 2004 Discontinued - Phase-I/II for Malignant melanoma in Europe (unspecified route)
- 04 Aug 2004 Discontinued - Preclinical for Ovarian cancer in Germany (unspecified route)